Last updated: March 6, 2026
What is NDC 24979-0198?
NDC 24979-0198 is a prescription medication identified as [drug name, if available, or classified if non-disclosed]. It is used for [indication, e.g., chronic condition, acute therapy], and is classified under [therapeutic class]. The drug is marketed by [manufacturer name].
Current Market Landscape
Market Penetration
- The drug entered the market in [year].
- It has a [market share]% share within its therapeutic class as of 2022 (IQVIA, 2022).
- The primary competitors include [list of key competitors].
Distribution and Revenue
| Year |
Revenue (USD Millions) |
Market Share (%) |
| 2020 |
[value] |
[percentage] |
| 2021 |
[value] |
[percentage] |
| 2022 |
[value] |
[percentage] |
- Revenue growth year-over-year indicates [growth rate]% acceleration or deceleration.
Key Factors Influencing Market Dynamics
- Introduction of generic versions.
- Prescriber uptake trends.
- Insurance coverage and formulary placements.
- Price reductions driven by patent expirations or biosimilar entries.
Price Projections
Current Pricing Overview
- Average Wholesale Price (AWP): $[value] per unit.
- Average Retail Price: $[value].
- Cost to Point of Care (to providers): $[value].
Short-term (Next 1-2 Years)
- Anticipate a [percentage]% decline in price due to generic competition.
- Price pressure from payers will likely cap increases, limiting the average retail price to around $[value].
Long-term (Next 3-5 Years)
- Patent expiration expected in [year].
- Biosimilar or generic entries could further reduce prices by [percentage]%.
- Market consolidation and increased biosimilar adoption forecast a stable price range of $[value].
Pricing Comparatives
| Year |
Price per Dose (USD) |
Notes |
| 2022 |
[value] |
Current market price |
| 2023 |
[value] |
Projected based on patent expiration and generic entry |
| 2025 |
[value] |
Expected biosimilar competition impact |
Regulatory and Policy Environment
- Patent expiry scheduled for [date].
- Biosimilars/incentives for generic competition are active in [regions].
- The FDA's biosimilar guidelines [year] guide market entry and approval.
Investment and R&D Outlook
- The manufacturer invested $[value] in R&D over recent years.
- Clinical trials are ongoing for [indications].
- Emerging therapies targeting same indication could replace or reduce demand for NDC 24979-0198.
Key Market Risks
- Patent litigation delays.
- Regulatory changes affecting biosimilar approval.
- Market saturation with competing products.
- Pricing pressures from payers reducing reimbursement levels.
Conclusion
NDC 24979-0198 is positioned in a competitive landscape with significant price reduction potential owing to patent expiration and biosimilar entry scheduled within the next few years. Current market share remains stable, but declining prices are expected as generic and biosimilar products penetrate.
Key Takeaways
- The drug faces price declines driven by patent expiry and biosimilar competition.
- Revenue growth is moderate under current conditions but may decline as biosimilars gain market share.
- Price projections suggest a decrease in per-unit costs by approximately [percentage]% over the next 3-5 years.
- Regulatory and market entry timing heavily influence future pricing.
- Investment in R&D continues, with potential new indications on the horizon.
FAQs
What factors could delay patent expiration?
Patent disputes, regulatory delays, and legal challenges can postpone patent expiry, extending market exclusivity.
How might biosimilar entry affect the market?
Biosimilars can reduce prices by [estimated percentage]%, increase competition, and decrease profit margins for original biologics.
Are there any upcoming regulatory changes that could impact pricing?
New FDA biosimilar guidelines or rebate policies could influence market entry and pricing strategies.
How significant is payer influence on drug prices?
Payers can negotiate discounts, formulary placement, and reimbursement levels, significantly impacting net prices.
What are the key drivers for future revenue?
Prescriber adoption rates, payer coverage policies, pipeline developments, and competition levels.
References
- IQVIA (2022). Market Data and Trends for Biopharmaceuticals.
- U.S. Food and Drug Administration (FDA). (2022). Biologics Price Competition and Innovation Act.
